Jeremy Pantin, MBBS, FACP
Dr. Jeremy Pantin obtained his degree in medicine and surgery from the University of the West Indies in St. Augustine, Trinidad and Tobago. Following this, Dr. Pantin completed his residency training in Internal Medicine at Howard University Hospital in Washington, DC, before pursuing his fellowship training in Hematology, Medical Oncology, and Blood and Marrow Transplantation at the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, Maryland.
After his fellowship, Dr. Pantin was appointed as a Staff Clinician at the NHLBI, where he gained continued clinical experience and conducted clinical and translational research in stem cell transplantation. He then went on to become an Associate Professor at the Medical College of Georgia, Augusta University Medical Center, and the Georgia Cancer Center in Augusta, GA. During his time at MCG, Dr. Pantin served as the Director of the Hematology and Medical Oncology Fellowship Program and as the Interim Director of the Blood and Marrow Transplant Program.
Currently, Dr. Pantin works as an attending transplant and cell therapy physician and clinical investigator, and is the Clinical Director of the Sarah Cannon Transplant and Cellular Therapy Network Program in Nashville, TN. In this role, he continues to provide specialized care to patients with complex hematologic conditions while also contributing to clinical trials in transplant and cellular therapy.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:Bristol Myers SquibbTopic:Speakers BureauDate added:09/04/2024Date updated:09/04/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:SanofiTopic:Speakers BureauDate added:09/04/2024Date updated:09/04/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:OmerosTopic:Speakers BureauDate added:09/04/2024Date updated:09/04/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:OmerosTopic:Advisory BoardDate added:09/04/2024Date updated:09/04/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:NovartisTopic:Advisory BoardDate added:09/04/2024Date updated:09/04/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Legend BiotechTopic:Advisory BoardDate added:09/04/2024Date updated:09/04/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:MaaT PharmaTopic:Advisory BoardDate added:09/04/2024Date updated:09/04/2024